car-t

Administering immunotherapy when the tumor microenvironment is most susceptible to T cells enhances treatment efficacy in mice.

Precision medicine helps clinicians tailor individual treatments, addressing genetic mutations, tumor microenvironment variations, and therapeutic resistance.

Find answers to common synthetic biology research questions in this collection of quick educational videos.

From early target discovery to preclinical development stages, researchers explore novel strategies for effective cell therapies in cancer treatment.

Automated counterflow centrifugation systems accelerate cell therapy workflow processes while maintaining cell yields and efficacy.

Download this eBook to take a closer look at past efforts, modern challenges, and future advances!

Pharmaceutical giant Sanofi to take over hemophilia drugmaker Biovertiv, while Celgene will buy cancer drugmaker Juno Therapeutics.

The results of two small clinical trials show that the immunotherapy is effective for multiple myeloma patients, at least in the near term.

The company has shuttered its experimental cell and gene cancer therapy unit, firing more than 100 researchers.

Juno Therapeutics asks the US Food and Drug Administration for permission to restart the CAR-T experiments without chemotherapy.

Corrections give belated credit for immunotherapy; mosquitoes have been bugging us long before Zika; the bright side of irreproducibility